Delivery Order SPE2DB20D3101-SPE2DB26FQTC8
- Not listed
- The Defense Logistics Agency awarded a $16,403.16 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This firm fixed price, non-competitive delivery order is set to be completed by August 29, 2025, with performance executed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a $30,113.19 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 mL pen injectors, with an ultimate completion date of November 3, 2025. This non-competitive delivery order was issued on October 31, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.64 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed price, non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order valued at $8,304.30 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 mL pen injections on September 18, 2025, with an ultimate completion date of September 19, 2025. This competitive, non-set-aside award utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections with a ceiling value of $5,141.16. This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The order is set for completion by September 11, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a $24,402.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on August 21, 2025, with completion scheduled for August 22, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. The award was made...
- The Defense Logistics Agency awarded a $7,509.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on August 19, 2025, with ultimate completion scheduled for August 20, 2025. This competitive award, placed under no set-aside designation, represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement...
- The Defense Logistics Agency awarded a $6,970.68 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. This award represents a non-set-aside competitive procurement, demonstrating AmerisourceBergen's continued capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,134.73 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on November 6, 2025, with completion expected by November 7, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a $42,647.15 delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Zepbound 10 mg/0.5 ml pen injectors. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The products will be delivered to AmerisourceBergen's corporate office...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB26FQTC8Delivery Order
The Defense Logistics Agency awarded a $34,638.78 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injectors on November 4, 2025, with completion scheduled for November 5, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion comprehensive global pharmaceutical support vehicle running through December 2026. The award was competitively procured with no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used in diabetes and weight management treatment, reflecting the Defense Logistics Agency's role in supplying essential pharmaceuticals to military and veteran healthcare systems. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen maintains extensive capability to fulfill federal medical procurement requirements across diverse therapeutic domains, including specialty medications, vaccines, and medical supplies. This delivery order exemplifies the company's ongoing support of the Defense Health Agency and broader military healthcare programs through the DLA's pharmaceutical prime vendor network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $34.6k | 11/4/25 |